Daily Reporter

Are we reaching a turning point in metastatic prostate cancer?

At yesterday’s Presidential Symposium, a Late-Breaking Abstract presentation of the PROfound study reported a clinically meaningful benefit in radiological progression-free survival (PFS) with olaparib in men with BRCA1, BRCA2 or ATM mutations in metastatic castration-resistant…

Read More

Mature data from immunotherapy trials at ESMO 2019

At ESMO Congress 2019, starting from Friday 27 September in Barcelona, Spain, immunotherapy will confirm to continue to lead the global oncology scene with mature data from several trials being presented at the main sessions….

Watch Here

Practice-changing results in NSCLC are expected

At ESMO Congress 2019, phase III FLAURA trial is one of the much awaited studies in lung cancer, according to Alessandra Curioni Fontecedro, University Hospital Zürich, Switzerland and Associate Editor of the Daily Reporter. Overall…

Watch Here